Hari P. Miskin
- Genetics top 1%
- Pathology and Forensic Medicine top 2%
- Oncology top 10%
- Immunology top 10%
- Molecular Biology
- Co-authors
- Peter SportelliMichael WeissMarshall T. SchreederOwen A. O’ConnorChangchun DengJohn G. KuhnIan W. FlinnDanielle M. Brander
- Topics
- Chronic Lymphocytic Leukemia Research (55 papers)Lymphoma Diagnosis and Treatment (29 papers)Monoclonal and Polyclonal Antibodies Research (17 papers)
- Partner nations
- United StatesAustraliaPoland
In The Last Decade
Hari P. Miskin
63 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 56
- Genetics 699
- Pathology and Forensic Medicine 676
- Oncology 315
- Immunology 297
- Molecular Biology 262
Countries citing papers authored by Hari P. Miskin
This map shows the geographic impact of Hari P. Miskin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hari P. Miskin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hari P. Miskin more than expected).
Fields of papers citing papers by Hari P. Miskin
This network shows the impact of papers produced by Hari P. Miskin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hari P. Miskin. The network helps show where Hari P. Miskin may publish in the future.
Co-authorship network of co-authors of Hari P. Miskin
This figure shows the co-authorship network connecting the top 25 collaborators of Hari P. Miskin. A scholar is included among the top collaborators of Hari P. Miskin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hari P. Miskin. Hari P. Miskin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 4 | |
| 4 | 1 | |
| 5 | TG-1701 A selective bruton tyrosine kinase (btk) inhibitor, as monotherapy and in combination with ublituximab and umbralisib (u2) in chronic lymphocytic leukemia (cll) and lymphoma | 1 |
| 6 | 39 | |
| 7 | 8 | |
| 8 | 64 | |
| 9 | 56 | |
| 10 | 90 | |
| 11 | 1 | |
| 12 | 61 | |
| 13 | 4 | |
| 14 | 44 | |
| 15 | 2 | |
| 16 | 9 | |
| 17 | 11 | |
| 18 | 8 | |
| 19 | 13 | |
| 20 | 4 |
About Hari P. Miskin
Hari P. Miskin is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology, having authored 66 papers that have together received 1.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (55 papers), Lymphoma Diagnosis and Treatment (29 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). The work is most often cited by research in Genetics (699 citations), Pathology and Forensic Medicine (676 citations) and Hematology (189 citations). Hari P. Miskin has collaborated with scholars based in United States, Australia and Poland. Frequent co-authors include Peter Sportelli, Michael Weiss, Marshall T. Schreeder, Owen A. O’Connor, Changchun Deng, John G. Kuhn, Ian W. Flinn, Danielle M. Brander, Swaroop Vakkalanka and Emmanuel Normant. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.